Overview

Phase 2 Study of VGT-309 in Lung Cancer

Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
A Phase 2 open label study to evaluate safety and efficacy of VGT-309 to identify cancer in up to 40 subjects undergoing lung cancer surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Vergent Bioscience, Inc.